Mr. Donald McCaffrey reports
RESVERLOGIX UPDATE
Resverlogix Corp. has received
confirmation that its European patent application covering RVX-208 has
been granted. European patent No. 2118074 is titled "Compounds for the
prevention and treatment of cardiovascular diseases." The patent life
will extend to February, 2027.
"We are delighted to have confirmation of this news," stated Don
McCaffrey, president and chief executive officer of Resverlogix. "This additional patent
builds upon the growing patent estate for RVX-208, our core asset. With
a patent life out to 2027, RVX-208 now has critical protection for the
next 13 years in the important European marketplace," Mr. McCaffrey added.
In addition, Resverlogix has also filed for a fixed-dose combination
patent, with Rosuvastatin, that if granted will extend the patent life
to 2033.
Resverlogix also announced that it entered into a waiver agreement with
RVX Therapeutics Inc., a wholly owned subsidiary
of Zenith Epigenetics Corp., whereby Resverlogix agreed to waive its
right under a licence agreement dated June 3, 2013, to license any
method or pharmaceutical agent within the scope of certain licensee
patents owned or controlled by RVX Therapeutics that may be determined
to come within the Apolipoprotein A-I (ApoA-I) therapeutic field (as defined in the license
agreement), and RVX Therapeutics agreed not to develop any patents
and/or compounds for any indication within the ApoA-I therapeutic field
for a period of five years. RVX Therapeutics agreed to pay Resverlogix
$2.5-million in cash and granted to Resverlogix a right of first
refusal for a period of three years thereafter in respect of the
licence or sale of such patents and/or compounds that are determined to
come within the ApoA-I therapeutic field. Entering into the waiver
agreement generated cash for Resverlogix without impacting on its core
assets.
In unrelated news, the company also announced that a March publication
in cell metabolism titled "High Density Lipoproteins and
Cerebrovascular Integrity in Alzheimer's Disease" includes discussion
of RVX-208, Resverlogix's small molecule ApoA-I modulator, as a
potential therapeutic for Alzheimer's disease (AD) (Stukas et al., 2014
Cell Metabolism 19:1-18). Prior exploratory clinical data on the
effect of RVX-208 on plasma amyloid beta levels, performed from the
phase Ia and phase II Assert studies, are discussed. As these earlier
cardiovascular trials were not specifically designed to study
Alzheimer's disease, efforts are being undertaken to advance an
exploratory trial in an AD patient population. The company is planning
a phase II clinical trial for the exploratory assessment of Alzheimer's
disease following treatment with RVX-208 in patients with Alzheimer's
and Alzheimer's-like dementia of possible vascular origin. The trial
will target mild to moderate Alzheimer's disease patients.
Additionally, Resverlogix has restructured its clinical cardiovascular disease program,
which will now be formally directed by Dr. Jan Johansson. The company
would like to thank Dr. Allan Gordon for his years of service and
wishes him great success in his future endeavours.
About RVX-208
RVX-208 is a first-in-class small molecule that inhibits BET
bromodomains. RVX-208 functions by removing atherosclerotic plaque via
reverse cholesterol transport (RCT), the natural process through which
atherosclerotic plaque is transported out of the arteries and removed
from the body by the liver. RVX-208 increases production of
Apolipoprotein A-I (ApoA-I), the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT.
These newly produced, functional HDL particles are flat and empty, and
can efficiently remove plaque and stabilize or reverse atherosclerotic
disease. Analysis of recent clinical trials data showed that RVX-208
significantly reduces coronary atherosclerosis and major adverse
cardiac events in patients with CVD who have a low level of HDL and
elevated C-reactive protein (CRP), a population with unmet medical need. ApoA-I may also
exert beneficial effects in Alzheimer's disease and diabetes mellitus.
RVX-208 also has anti-inflammatory effects including effects on interleukin-6 inhibition, vascular cell adhesion-1 and monocyte
chemotactic protein-1, factors known to be involved in atherosclerosis
and plaque stability.
We seek Safe Harbor.
© 2024 Canjex Publishing Ltd. All rights reserved.